Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ON long-term extension of oral BI 1015550 in IPF and PPF
2023-507353-15-00Phase 3Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2024
- Modality
- Small Molecules
- Countries
- 44
01
Overview
Phase 3, open-label, single-arm trial of nerandomilast in idiopathic pulmonary fibrosis (IPF) and pulmonary fibrosis (PF), sponsored by Boehringer Ingelheim. Primary endpoint: Any adverse event. Planned start Sep 2024; status: authorised.
02
Drugs
nerandomilast
03
Conditions
idiopathic pulmonary fibrosis (IPF)pulmonary fibrosis (PF)
Beyond the preview
Go deeper on 2023-507353-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-507353-15-00.